The Lead Podcast - Episode 38

Janice Y. Chyou, MD, FHRS, of Icahn School of Medicine at Mount Sinai is joined by guests Jonathan P. Piccini, Sr., MD, MHS, FHRS, of Duke University Medical Center, and Mintu P.Turakhia, MD, MS, of iRhythm Technologies and Stanford University to have A Discussion of Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation. Subclinical atrial fibrillation is short-lasting and asymptomatic and can usually be detected only by long-term continuous monitoring with pacemakers or defibrillators. Subclinical atrial fibrillation is associated with an increased risk of stroke by a factor of 2.5; however, treatment with oral anticoagulation is of uncertain benefit. Among patients with subclinical atrial fibrillation, apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding.

https://www.hrsonline.org/education/TheLead

https://www.nejm.org/doi/full/10.1056/NEJMoa2310234

Host Disclosure(s):

J. Chyou: Honoraria/Speaking/Consulting Fee: McGraw-Hill, American Heart Association; Membership (Advisory Committee): American Heart Association

Contributor Disclosure(s):

J. Piccini: Honoraria/Speaking/Consulting Fee: Biotronik, AbbVie, LivaNova, Boston Scientific, Phillips, Medtronic, Electrophysiology Frontiers, Abbott, UpToDate, Inc., Sanofi, Milestone Pharmaceuticals, Bayer Healthcare Pharmaceuticals; Research (Contracted Grants for PIs Named Investigators Only): Boston Scientific, Bayer Healthcare Pharmaceuticals, AMA, Abbott, Phillips, Element Science, Inc., iRhythm Technologies, NIH

M. Turakhia: Research (Contracted Grants for PIs Named Investigators Only): Bristol-Myers Squibb, FDA Circulatory System Devices Panel, American Heart Association, Bayer Healthcare Pharmaceuticals, Sanofi; Stocks (Board Membership): 100Plus; Employment: iRhythm Technologies